Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Abstract Alzheimer’s disease (AD) is characterized by progressive cognitive decline, severe brain atrophy and neuroinflammation. We conducted a randomized, double-blind, placebo-controlled, parallel-group phase 2a clinical trial that tested the safety and efficacy of laromestrocel, a bone-marrow-der...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Brian G. Rash, Kevin Ramdas, Nataliya Agafonova, Eric Naioti, Lisa McClain‐Moss, Zarin Zainul, Brittany Varnado, Kevin Peterson, Michael Brown, Thiago Peixoto Leal, Steven Kopcho, Raul Carballosa, Paayal Patel, Mark Brody, Brad Herskowitz, Ana Fuquay, Savannah Rodriguez, Alan F. Jacobson, Ramón Fernández de León, Michael A. Pfeffer, Julie Schwartzbard, Jeffrey Botbyl, Anthony A. Oliva, Joshua M. Hare
Format: Artigo
Idioma:anglès
Publicat: 2025
Accés en línia:https://doi.org/10.1038/s41591-025-03559-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Internet

https://doi.org/10.1038/s41591-025-03559-0

Ítems similars